A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

被引：0

作者：

Ross, Robert W. ^{[1
]}

Srinivasan, Ramaprasad ^{[2
]}

Vaishampayan, Ulka ^{[3
]}

Bukowski, Ronald ^{[4
]}

Rosenberg, Jonathan ^{[5
]}

Eisenberg, Peter ^{[6
]}

Logan, Theodore ^{[7
]}

Srinivas, Sandhya ^{[8
]}

Stein, Mark ^{[9
]}

Mueller, Thomas ^{[10
]}

Keer, Harold N. ^{[10
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Natl Canc Inst, Urol Oncol Branch, Bethesda, MD USA

[3] Karmanos Canc Ctr, Detroit, MI USA

[4] Cleveland Clin, Cleveland, OH USA

[5] Univ Calif San Francisco, San Francisco, CA USA

[6] California Canc Ctr, Greenbrae, CA USA

[7] Indiana Univ, Ctr Canc, Indianapolis, IN USA

[8] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA

[9] Inst Canc Res, New Brunswick, NJ USA

[10] Exelixis Inc, San Francisco, CA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3511S / 3511S

页数：1

共 50 条

[1] A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)
Srinivasan, R.
Choueiri, T. K.
Vaishampayan, U.
Rosenberg, J. E.
Stein, M. N.
Logan, T.
Bukowski, R. M.
Mueller, T.
Keer, H. N.
Linehan, W. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[2] A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC)
Ross, R. W.
Stein, M.
Sarantopoulos, J.
Eisenberg, P.
Logan, T.
Srinivas, S.
Rosenberg, J.
Vaishampayan, U.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[3] A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC)
Srinivasan, R.
Linehan, W. M.
Vaishampayan, U.
Logan, T.
Shankar, S. M.
Sherman, L. J.
Liu, Y.
Choueiri, T. K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[4] The c-Met/VEGFR2 inhibitor XL880 inhibits ovarian cancer cell growth
Zillhardt, M.
Sawada, K.
Jagadeeswaran, S.
Temkin, S.
Yamada, D.
Buller, R.
Lengyel, E.
GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S132 - S133
[5] Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Choueiri, Toni K.
Vaishampayan, Ulka
Rosenberg, Jonathan E.
Logan, Theodore F.
Harzstark, Andrea L.
Bukowski, Ronald M.
Rini, Brian I.
Srinivas, Sandy
Stein, Mark N.
Adams, Laurel M.
Ottesen, Lone H.
Laubscher, Kevin H.
Sherman, Laurie
McDermott, David F.
Haas, Naomi B.
Flaherty, Keith T.
Ross, Robert
Eisenberg, Peter
Meltzer, Paul S.
Merino, Maria J.
Bottaro, Donald P.
Linehan, W. Marston
Srinivasan, Ramaprasad
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 181 - 186
[6] Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
Jhawer, M. P.
Kindler, H. L.
Wainberg, Z. A.
Hecht, J. R.
Kerr, R. O.
Ford, J. M.
Henderson, C.
Mueller, T.
Keer, H. N.
Shah, M. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] Visual Function Effects of Foretinib, a Dual MET/VEGFR2 Inhibitor, in a Phase 2 Study for Treatment of Papillary Renal Cell Carcinoma
Meyerle, Catherine
Srinivasan, Ramaprasad
Linehan, W. Marston
Yeh, Steven
Chew, Emily
Chan, Chi-Chao
Forooghian, Farzin
Ferris, Frederick
Zein, Wadih
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
[8] Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer
Logan, Theodore F.
CURRENT ONCOLOGY REPORTS, 2013, 15 (02) : 83 - 90
[9] Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer
Theodore F. Logan
Current Oncology Reports, 2013, 15 : 83 - 90
[10] Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors
Eder, J. P.
Heath, E.
Appleman, L.
Shapiro, G.
Wang, D.
Malburg, L.
Zhu, A. x.
Leader, T.
Wolanski, A.
LoRusso, P.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →